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Abstract
Prediction of patient-centered outcomes in hospitals is useful for performance benchmarking, resource allocation, and
guidance regarding active treatment and withdrawal of care. Yet, their use by clinicians is limited by the complexity of
available tools and amount of data required. We propose to use Disjunctive Normal Forms as a novel approach to predict
hospital and 90-day mortality from instance-based patient data, comprising demographic, genetic, and physiologic
information in a large cohort of patients admitted with severe community acquired pneumonia. We develop two algorithms
to efficiently learn Disjunctive Normal Forms, which yield easy-to-interpret rules that explicitly map data to the outcome of
interest. Disjunctive Normal Forms achieve higher prediction performance quality compared to a set of state-of-the-art
machine learning models, and unveils insights unavailable with standard methods. Disjunctive Normal Forms constitute an
intuitive set of prediction rules that could be easily implemented to predict outcomes and guide criteria-based clinical
decision making and clinical trial execution, and thus of greater practical usefulness than currently available prediction tools.
The Java implementation of the tool JavaDNF will be publicly available.
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Introduction and Background
Sepsis and Critical Care
Among inflammatory illnesses, pneumonia often presents as
sepsis, defined as infection accompanied by systemic signs and
symptoms of infection [1], including rapid heart rate, rapid
respiratory rate, and fever. Approximately 750,000 patients
develop severe sepsis each year in US, with a hospital mortality
rate of 28.6%, or 215,000 deaths per year [2]. A significant
number of these patients have pneumonia [3]. Interventions for
severe sepsis that decrease morbidity and mortality could
profoundly impact public health [4]. There is ample pre-clinical
and clinical evidence that immunomodulation improves the
outcome of patients at higher risks of death, yet pre-clinical data
and simulation have also indicated that harm may ensue from
targeting some subpopulations of patients [5–7]. Early detection of
patients at high risk of developing organ dysfunction and death has
proved challenging.
Tools to predict the outcomes of critical illness have been
developed for three decades [8–12]. Most of these prediction tools
are logistic regression models, presumably because of their
popularity and ease of interpretation of odds ratios associated
with predictors of outcome. Yet, logistic regression is intolerant of
missing data, does not readily deal with correlated data, and it may
be difficult to quickly generate a prediction for the non-expert. A
desirable prediction tool should possess the following properties:
discrimination (the ability to classify the outcome of patients that
who will develop hospital mortality and who will not), learnability
(the ability to achieve the discrimination from moderate quantity
of data and few features, especially in the early detection of critical
care where fewer data are available), completeness (explore the
solution space as completely as possible under appropriate
assumptions), transparency (not behave as a ‘‘black box’’), and
having the ability to be easily interpretable by the end-user,
typically a non-expert.
We propose to use short Disjunctive Normal Form (DNF;
‘‘OR’’ of ‘‘AND’’) as an appropriate representation of the
hypothesis space to predict critical care outcomes because 1)
DNF is a high order boolean function that examines potentially
complicated relationships between predictors and outcomes, 2)
DNF offer great flexibility and allows identification of unforeseen
interactions between predictors, 3) DNF is a natural form of
knowledge representation for humans to interpret and they
provide clinical insights and clear rules to assist in decision
making, 4) DNF is scalable to large or small datasets. A short DNF
increases interpretability of the rules and mitigates overfitting bias.
The aim of this study was to illustrate the ability of DNF to predict
hospital and 90-day mortality within 2 days of admission in
patients with community acquired pneumonia.
Related work
Previous models have been limited by retrospective design, [13–
16] the dependence on large hospitalization data [13–19], the lack
of interpretability of complex models [16], restricted applicability
to single study sites [15,18,20], and bias to certain patient
populations [15,16,18]. Time dependent techniques as alternatives
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to standard Cox proportional hazard models [21] and dynamic
microsimulation [22] have also been published [23] [24]. Both
microsimulation and Markov transition kernels derived in these
publications are learned from population-level inference and are
not instance-based (i.e. patient-specific). We also have the intuition
that, outside the framework of a clinical study, clinical data are
collected on the basis of perceived clinical need and thus
missingness is highly likely not random. Accordingly, there is a
very good case to be made that models based on instances might
perform better than population models.
From a computational point of view, existing work on outcome
prediction models in the clinic learn from a training data set and
test their performance using a test data set, such as support vector
machine (SVM) regression [25], decision tree classification [26],
neural network [27,28], recursive partitioning [29], linear stepwise
regression [30], support vector regression [31], least-squares
regression [31][32], and least angle regression [31]. This body of
work focuses on the prediction quality in a cross validation
manner. A general flaw associated with models based on these
techniques is the absence of clinically meaningful and interpretable
functions. Such easily applicable rules would be very desirable
indeed in contexts where protocolization of medical decision
making, real-time rule-based alerting, or resource allocation is
important. Rule induction algorithms, such as decision tree
algorithm, [33] and ordered list of classification rules induction
[34] can also mine if-then rules. While decision trees can be
converted to DNF, the function forms are less flexible due to the
constraints of tree structure. Another key difference is that our goal
focuses on learning the shortest DNF while decision trees aim at
either the fast computational efficiency (heuristic algorithm) or
prediction performance (cross-validation test and tree pruning).
Sequence analyses using logic regression [35] and Monte Carlo
logic regression [36] adaptively identify weighted logic terms that
are associated with outcomes; the weakness shared by the random
sampling algorithm is the incomplete exploration of the entire
hypothesis space.
Materials and Methods
The GenIMS study cohort
Patients with community acquired pneumonia (CAP), a
common cause of sepsis, were recruited as part of the Genetic
and Inflammatory Markers of Sepsis (GenIMS) study, a large,
multicenter study of subjects presenting to the EDs of 28 teaching
and non-teaching hospitals in 4 regions in the United States
(Western Pennsylvania, Connecticut, Michigan, and Tennessee)
between November 2001 and November 2003. Eligible subjects
were w18 years and had a clinical and radiologic diagnosis of
pneumonia, as per the criteria of Fine, et al. [21]. Further details
on inclusion and exclusion criteria are provided elsewhere [22].
The GenIMS study was approved by the Institutional Review
Boards of the University of Pittsburgh and all participating sites.
The current study used fully de-identified data and was approved
by the University of Pittsburgh IRB.
Of the 2320 patients enrolled, we restricted our analysis to 1815
subject admitted to the hospital and with measurements of serum
inflammatory markers data on enrollment day. Our primary
outcomes were all-cause mortality at hospital discharge and at 90
days after enrollment.
Measurements
The dataset included demographic information, diagnostic
information as to bacterial etiology and anatomical site of sepsis,
admission APACHE III as an indicator of overall disease severity
[23], organ level physiologic variables to quantify organ dysfunc-
tion, routine laboratory markers, and interventions. Relevant to
our analysis, the inflammatory markers IL-6, IL-10, tumor
necrosis factor (TNF), and lipopolysaccharide binding protein
(LBP) were collected on days 1, 2, 3, 4, 5, 6, 7, 8, 15, 22 and 30
while patients were still in the intensive care unit. An extended set
of coagulation studies was collected on day 1, as well as an array of
fluorescent antibody cell sorting (FACS) markers to quantify
different immune cell populations on day 1. Finally, DNA
information on 27 single nucleotide polymorphism (SNP), each
segregating the study population in non-overlapping binary or
ternary genotypic categories, was also collected. There were
chosen because they were previously shown or suspected to have
prognostic value in sepsis [24,37–39].
Learning the classifier as Disjunctive Normal Form (DNF)
Conceptually DNF is a disjunction of conjunctions where every
variable or its negation is represented once in each conjunction.
The learning of DNF is a machine learning technique to infer
Boolean function relevant with a class of interest. It has been
extensively used in electric circuit design, information retrieval
[40], chess gaming [41], and so on. Formally, a Disjunctive
Normal Form (DNF) is a standardization boolean function, which
is a disjunction of conjunctions, where the conjunctions consist of
one or more positive and negative literals (statement about the
data). Any given boolean function f : f0,1gd?f0,1g can be
converted into an equivalent DNF. The following is an example
DNF formula:
f (x1,x2,x3)~
(x1 AND x3) (x1 AND :x2 AND x3) x2
ð1Þ
where ‘:’ denotes negation, and ‘xi’ denotes a binary literal,
indicating whether a particular test ‘‘Feature~Value’’ is true. A
DNF formula is essentially a set of Boolean logic if-then rules,
describing how the Boolean outcome is calculated based on
Boolean inputs.
DNF are traditional binary classifiers that predict Boolean
outcomes from instance-based data. The size of DNF functions is
2-dimensional: the number of conjunctive clauses and the
maximum number of literals in each clause, thus a DNF is usually
represented as k-term n-DNF, where k and n are the number of
clauses and maximum number of literals respectively. In DNF
learning, k and n are usually regularized because, without
constraints, k and n tend to become very large, result in
overfitting, thus compromising generalizability. Finding the
minimum size DNF formula is a well-known NP-Complete
problem [42,43]. There is no polynomial time learning algorithm,
and existing practical solutions usually sacrifice completeness for
efficiency. The existing heuristic or approximation approaches fall
into deterministic [40,44,45] and stochastic algorithms [41,46].
The deterministic methods include bottom-up schemes (learning
clauses first and building DNF in a greedy way) and top-down
schemes (converting DNF learning to a Satisfiability problem).
Stochastic methods randomly walk through the solution space to
search for clauses but are not guaranteed to yield optimal
solutions. Our group developed two heuristic algorithms to
accelerate the DNF learning by narrowing the solution space
under the domain assumptions: standalone DNF learning, and
monotone DNF learning (MtDL), described more fully in
Appendix S1.
Considered as a core algorithm in concept learning, DNF suffer
from shortcomings: 1) the learnability of DNF has been a
Prediction of Patient Hospital Mortality
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fundamental and hard problem in computational learning theory
for more than two decades, 2) DNF are sensitive to errors in data,
as are all Boolean function learning algorithms, 3) without the
constraint of size, DNF may suffer from a severe overfitting bias.
Our group has been developing algorithms for accelerating and
optimizing DNF learning and has been applying the techniques to
biomedical data. We specifically focus on short DNF learning to
learn meaningful rules as well as to avoid overfitting.
Model hierarchy and benchmark classifiers
We construct a hierarchy of models 1 to 8 incrementally
including features pertaining to different domains of data (Table 1).
Model 8 is the most complete model containing all available
features; Model 7 is a complete set of features, but restricted to
data available only on day 1 of hospital, while Models 1 to 6
include selective domains of features. No data beyond day 2 post-
enrollment were included in the predictions.
To compare the performance of the DNF learning algorithm, a
number of other classifiers were constructed. These include simple
Logistic Regression, Naive Bayes, SVM, Multi-layer Perceptron
(Neural Network), and tree-based algorithms, (e.g. Random Tree,
and Random Forest). Prior to classification, all continuous data
were discretized in terciles (age), or quartiles (all analytes and
APACHE score). For each model, two feature selection algorithms
(information gain ranking and chi-square ranking) were run to
select a maximum of 15 predictor variables (features). Feature
selection was applied using 10-fold cross-validation to mitigate
overfitting. Benchmark classifiers used the union of feature sets
identified by the selection algorithms.
Performance metrics
We evaluate the models ability to discriminate outcome by
received operating characteristics (ROC) area under the curve.
Sensitivity and specificity are also provided. We computed the
Brier score as a global measure of calibration. For DNF, we also
adapted the Hosmer-Lemeshow H-statistic (AHL) to binary
outcomes [47]. Because DNF learning outcomes are either 0s or
1s, we created five bins including a geometrically larger number of
predicted deaths. We randomly choose predicted survivors to
complete the bins which comprised an approximately equal
number of patients. The AHL was then computed as a chi-squared
statistic across the five bins [48]. For the probability-based models,
e.g., Logistic Regression and SVM, we use their binary outcomes
instead of the continuous probability to compute the AHL statistics
scores. All metrics are reported in the entire population and in the
external validation cohort.
Results
Patient characteristics
All 1815 patients had demographic, disease severity and at least
two inflammatory markers measured on day 1. The number of
patients were different domains of data were available varied and
was least for FACS (Figure 1). This distribution strongly
determined the hierarchy of models examined. A complete
description of cohort demographics and physiology has been
published [22].
Predictors identified by benchmark classifiers
Clinical markers of severity (APACHE score and number of
failing organ systems) were the strongest predictors of both hospital
and 90-day mortality. Of demographic features, only age and the
presence of chronic illness were included in most predictive
models. Most SNPs examined were uncorrelated to 90-day
mortality, but IL6M174 (GG), L100M1048 (G/T) and MIFM173
(GG) were consistently predictive, even in multivariate models.
IL18M137 was less consistently associated with outcome. Features
also consistently selected in the hierarchy of models included
monocyte positivity for CD-14 and CD-120a, and monocytic and
granulocytic positivity for toll-like receptor (TLR)-2. Although it
could be that the 10-fold cross-validation procedure admitted
significant overfitting (N= 124), it is an interesting hypothesis that
Table 1. Predictors (features) inluded in the different models.
Model Features included
Model 1 Demographics (age, sex, race, chronic, disease), Macrophysiology (APACHE III score, number of organ system failure on day 1)
Model 2 Demographics, physiology, day 1 cytokines
Model 3 Demographics, physiology, SNP profile
Model 4 Demographics, physiology, day 1 cytokines, SNP profile
Model 5 Demographics, physiology, day 1 cytokines, SNP profile, coagulation data
Model 6 Demographics, physiology, FACS
Model 7 Demographics, physiology, day 1 cytokines, SNP profile, coagulation data, FACS
Model 8 Demographics, physiology, all available cytokines, SNP profile, coagulation data, FACS
doi:10.1371/journal.pone.0089053.t001
Figure 1. Availability of data across physiologic domains. Of
1815 patients with cytokine data on day 1, much smaller numbers of
patients had single nucleotide profiles (SNP), Fluorescent-Antibody Cell
Sorting (FACS) measurements of surface markers, or full coagulation
studies (Coags)performed.
doi:10.1371/journal.pone.0089053.g001
Prediction of Patient Hospital Mortality
PLOS ONE | www.plosone.org 3 April 2014 | Volume 9 | Issue 4 | e89053
the profile of activation of immune cells conveys as much or more
information than cytokines and SNP polymorphisms.
DNF learning algorithm prediction performance
The DNF learning prediction quality is first evaluated by its
discrimination. The ROC curve (Figure 2) is generated upon
tuning the sensitivity/specificity weights in the optimization
objective function. The AUC for hospital mortality dataset in
Model 8 is 0.937, which is very similar to the performance
obtained with Model 7, suggesting that serum inflammatory
markers levels after day 1 do not contribute much to the predictive
ability. This is a meaningful result as hospital mortality is by and
large determined by data obtained on the first admission day.
90-day mortality is considerably more difficult to predict than
hospital mortality with the AUC decreasing to 0.785. We again
compare the performance on Model 7, Model 8, and also add day
2 serum inflammatory marker levels to Model 7, without
significant improvement in predictive ability (Figure 2). The
DNF learning algorithm outperforms other benchmark classifiers
built from Model 7 and Model 8 (Table 2), even if Model 8
contains a much more complete set of features; however Naive
Bayes and Logistic Regression model prediction performance are
lower than that of Model 7 because these two models lack of
regularization; Random tree and Random Forests’ implementa-
tions we used do not implement pruning and result in severe
overfitting issues; on the other hand, Boosted Logistic and DNF
naturally implements regularizations and perform as well as Model
7 (Table 2).
When removing features from Model 7 (Models 1 to 6), the
DNF learning accuracy decreases (Table 2). DNF learning also
outperforms other classifiers on Model 6, suggesting that models
which include FACS data perform well despite the modest size of
the cohort. For less rich Models 1 to 5, the performances of DNF
and benchmark classifiers were comparable, suggesting that
richness of the set of features contributes more to the predictive
ability of DNF compared to other classifiers. This conjecture could
be examined in computational experiments. Interestingly, Logistic
Regression-based classifiers performed consistently better than
other benchmark classifiers through Model 5 (Table 2).
DNF learning algorithm external validation
To evaluate the external validity of predictions from DNF
learning, we developed models using patients from a random
subset of 27 hospitals, comprising approximately two-thirds of the
patients. The prediction performance of DNF rules are then tested
on patients from the remaining six hospitals, where the numbers of
patients per hospital varied between 1 to 343.
Using 90-mortality as the outcome of interest the DNF learning
ROC achieves 0.789 which is similar to that we learned in cross-
validation over the entire cohort when using all the features. The
external validation performance of DNF learning compared
advantageously with that of benchmark models (Table 3). Of
note, DNF learning was the best calibrated model (AHL=9.06,
p = 0.06 with 4 df).
Specific rules learned from the data
The DNF learning algorithm simultaneously optimizes the
prediction quality and minimizes the length of DNF functions,
because without constraining the function length, the DNF
functions can be complicated and lead to severe over-fitting
problems. The DNF learning algorithms aim to learn the shortest
functions (see section 0 for the definition of the function length),
i.e. the most generic functions extracted from the data that can
discriminate the mortality outcomes. The DNF learned to predict
hospital mortality is:
(Ssday1w1) ((Ssday1w0)
AND (Npctw1) AND (NIL6 2w1))~z
ð2Þ
Figure 2. Prediction performance of DNF learning on hospital and 90-day mortality data. 10-fold cross validation is applied to assess the
prediction performance of DNF learning on hospital and 90-day mortality, and compare the performance when using the whole feature set (Model 8,
see Table 1) and only day 1 (Model 7) and/or day 2 cytokine (Model 7 + day 2 cytokines).
doi:10.1371/journal.pone.0089053.g002
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Where Feature~t means the value of the feature falls into
group t; Featurewt means the feature value is larger than that of
group t. Recall that the feature values are discretized into 3 to 5
groups, and the group values are indexed from 0 to N{1 where N
is the number of groups. The full explanation of literals appeared
in this study is shown in Table 4.
Function (1) indicates that if either one of two conditions is
satisfied, the outcome is predicted to be hospital death, where the
two conditions are 1) Ssday1 value is larger than 1 (failure in more
than one organ system), or 2) Ssday1 value is larger than 0 AND
Npct value is larger than 1 AND NIL6 2 value (quartile of IL-6
levels on the second day) is larger than 1. The positive symbol on
the right side of function (1) is positive label, i.e., hospital mortality.
Since all the DNF predict positive class, the ‘+’ symbol on the right
side is replaced with the sensitivity/specificity metrics of the DNF.
For representation purposes a DNF will be written as DNF= sen-
sitivity/specificity, and the above function is now:
(Ssday1w1) ((Ssday1w0)
AND (Npctw1) AND (NIL6 2w1))~93:6%=82:3%
ð3Þ
This DNF contains 2 terms of 4 literals covering 3 different
features: Ssday1, Npct, and NIL6 2, comprising only 3% of all
features available in the data, suggesting that DNF functions
discriminate the outcomes by only using a small fraction of the
feature sets (v10% features in all cases).
The prediction procedure implied by a DNF (3) is illustrated in
Figure 3. The prediction procedure of DNF is represented in three
layers: the top layer is the DNF itself; the middle layer is the clause
level; and the bottom layer is the final outcome. Red color
rectangles indicate that patient data is above the threshold and a
severity condition is met; green rectangles indicate that patient
data is below and the condition is not met. Three example patients
are shown. For patient A, Ssday1, Npct and NIL6 2 are all above
the threshold and results in a positive Clause 2 so the predicted
outcome is mortality. For patient B, Clause 2 is negative due to the
low Npct (procalcitonin in the lowest quartile); however high
Ssday1 turns on Clause 1 and predicts mortality too. Patient C has
high Npct but it is not sufficient to turn on either Clause 1 or 2 and
she is therefore predicted to survive.
The DNF learned from the data are shown in Table 5. For
hospital mortality, Ssday1 is a strong predictor. A high level of
Ssday1 is associated with high risk of mortality. IL6 and IL10 are
strong predictors too, and appear to be consistently predictive,
which can possibly support the concept that total inflammation, as
opposed to a balance between pro-inflammation and anti-
inflammation, is predictive of outcome [21]. IL6 on day 2 turns
out to be a strong predictor, yet needs two other conditions to also
be present (Equation (1) in Table 5). In Model 7, IL10 1 is selected
instead, and it needs 3 other conditions too: agew1, Ssday1w0
and IL1R901827 SNP is not A/G (Equation (2) in Table 5).
To predict 90-day mortality, the number of terms in DNF
increases to 5, and the sensitivity decreases to 80%, suggesting that
Ssday1 is not as strong a predictor of 90-day mortality as it is of
hospital mortality. In Model 8, Ssday1 combines with Npct factor
to form a single clause, and in Model 7 it needs Nap3. Higher
Nap3 is also an indication of high death risk. Interestingly
although SNP generally has low correlation with the 90-day
mortality, IL1R895495 and IL1R901827 are learned in the DNF.
The highest discriminator of poor outcome was the day 1 to day
2 trend in the product of IL-10 and IL-6. Trends in day 1 to day 2
TNF, IL-10, IL-6, were also retained in the models. This is a very
interesting, and somewhat refreshing observation, raising the
hypothesis that interventions significantly impacting early cytokine
profiles might indicate biological activity resulting in more
favorable long-term outcome.
Table 2. Comparative performance of models on predicting 90-day mortality.
Model NB SVM NN LOG BL RT RF DNF
Model 1 .740 .716 .746 .748 .755 .705 .743 .752
Model 2 .733 .697 .690 .747 .752 .673 .681 .740
Model 3 .709 .683 .742 .762 .763 .670 .696 .755
Model 4 .745 .714 .733 .762 .755 .662 .711 .749
Model 5 .770 .718 .728 .774 .766 .650 .654 .756
Model 6 .739 .689 .696 .728 .739 .690 .699 .759
Model 7 .783 .747 .751 .785 .766 .701 .715 .791
Model 8 .704 .744 .756 .723 .768 .575 .628 .785
NB-Naive Bayes, SVM-Support vector machine, NN-neural network, LOG-Logistic regression, BL-Boosted logistic regression, RT-Random tree, RF-Random forest, DNF-
Disjunctive Normal Form learning.
doi:10.1371/journal.pone.0089053.t002
Table 3. Comparative performance of models on predicting 90-day mortality.
Scores NB SVM NN LOG BL RT RF DNF
ROC .747 .752 .757 .738 .748 .655 .698 .789
1 - Brier Score .712 .750 .844 .822 .867 .792 .874 .891
NB-Naive Bayes, SVM-Support vector machine, NN-neural network, LOG-Logistic regression, BL-Boosted logistic regression, RT-Random tree, RF-Random forest, DNF-
Disjunctive Normal Form learning.
doi:10.1371/journal.pone.0089053.t003
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In the external validation, the DNF learned from the
development set is:
(Npctw1 AND Ssday1w0 AND Nap3w1) OR
(Nap3~4 AND IL1R895495 AG!~
G=A AND Npctw1 AND Nfcd120av4)
(chronic tw0 AND NIL6 3w1 AND IL1R895495 AG!~
G=A AND Ssday1w0)~81:8%=71:4%
ð4Þ
The first two clauses are similar to those learned in Table 5,
which indicated that 1) the process of DNF learning is robust in
identifying predictive rules if data used in development is
consistent with population data, and that 2) correlations in data
may allow similar, but not identical rules, when different
development sets are selected.
Discussion and Conclusion
We present a new class of models, DNF learning, which
produce data-driven rules predicting mortality in patients hospi-
talized with severe community acquired pneumonia (see Appendix
S1 for details). A distinctive feature of DNF, compared to
commonly presented prediction models, is that the resulting rules
are readily interpreted by clinicians and can be used to enhance
clinical decision making in a variety of contexts. These rules are
created under the assumption that DNF are an appropriate
representation of the manner data relate to outcome in severe
Table 4. DNF literals explanation.
literal meaning value type num of value groups
Ssday1 Presence of some organ dysfunction on day 1 [49] integer 5*
Npct Quartile of procalcitonin [50] integer 5
NIL6 2 Quartile of the inflammatory marker IL-6 on the second
day of admission
integer 5
IL1R901827A15 Genetic polymorphism of IL-1 receptor antagonist protein Gene 3
Nage Quartile of age integer 5
NIL10 1 Quartile of the inflammatory marker IL-10 on the day of
admission
integer 5
IL1R895495 AG Genetic polymorphism of IL-1 receptor antagonist protein Gene 5
Nap3 Quartile of APACHE III score integer 5
chronict Burden of chronic illness, as determined by the Charlson
index [51]
integer 5
Nfactor Quartile of coagulation Factor IX activity integer 5
Note*: when missing values present in the data, they are treated as a literal, but they are never selected in the DNF learning.
doi:10.1371/journal.pone.0089053.t004
Figure 3. Interpreting DNF models on three patients. The prediction procedure of DNF is represented in three layers: the top layer is the DNF
itself; the middle layer is the clause level; and the bottom layer is the final outcome. Red color rectangles indicate that patient data is above the
threshold and a severity condition is met; green rectangles indicate that patient data is below and the condition is not met. Three example patients
are shown. For patient A, Ssday1, Npct and NIL6 2 are all above the threshold and results in a positive Clause 2 so the predicted outcome is
mortality. For patient B, Clause 2 is negative due to the low Npct (procalcitonin in the lowest quartile); however high Ssday1 turns on Clause 1 and
predicts mortality too. Patient C has high Npct but it is not sufficient to turn on either Clause 1 or 2 and she is therefore predicted to survive.
doi:10.1371/journal.pone.0089053.g003
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community acquired phenomena. In other words, several alter-
native (disjunctions) mechanisms can contribute to the outcome,
each mechanisms represented by the conjunction of conditions.
The assumption is clinically plausible and important as we develop
algorithms to compute the DNF, because it reduces the hypothesis
space greatly and makes the computational hard problem solvable
in reasonable time. We demonstrated learning efficiency and
consistency on simulated sequences, showed the strength of the
methods in learning meaningful mapping functions and showed
superior prediction accuracy compared to other machine learning
methods on real clinical data.
The use of DNF as a prediction tool has several strengths.
Prediction rules are intuitive and easy to apply at the bedside
(Figure 3). They could be easily interfaced with the electronic
health record. Because a rule is comprised of separate disjunctive
statements, each or which can be true or false, its veracity can
typically be assessed even if partial data is available, and very soon
following an initial assessment of the patient. A popular mortality
prediction model, APACHE [49], requires 24 hours of observa-
tion before formulating a prediction. Another popular tool, MPM
[50], uses information available upon initial encounter, but is less
accurate and requires many more data elements to formulate a
prediction. Prediction models not based on logistic regression are
essentially black-box classifiers which provide little insight as to
which feature drives the prediction. In this regard, DNF are very
transparent in their use of data to generate a prediction.
We aimed to learn the minimum size DNF in spite of the fact that
the exact learning task is NP-complete [42,43]. Compared to existing
heuristic algorithms that only focus on learning time and learnability
[40,41,44–46], we exploit domain knowledge and develop efficient
exhaustive algorithms to learn the shortest DNF. We also applied a
number of techniques to accelerate the DNF learning process (see
Appendix S1 for details), including setting the maximum length of
clauses in standalone algorithm, using feature selector (CF) in MtDL
to narrow down the searching space, equivalence filtering of the
clauses, and extending both algorithms to greedy versions. This
enables the algorithms to run efficiently on large datasets. The DNF
learning algorithms are also powerful in extracting DNF from only a
small numbers of sequences where the data are reliable.
The approach achieves equivalent or higher prediction perfor-
mance compared to a set of state-of-the-art machine learning
models, and unveils insights unavailable with standard methods.
For example, we have shown that although predictive on their
own, the added benefit of genetic and cytokine data over
physiology and demographics-based classifiers was not spectacular
in identifying poor long-term outcome. It also appears that, if one
were to choose between a serum assay and a DNA profile (or SNP
screen) as an early predictor of outcome, both convey comparable
information with the possible exception of the product of serum
levels of IL6 and IL10, plausibly a (quite naive) integrator of the
magnitude of the inflammatory response. There are no currently
available point-of-care kits to measure cytokine panels reliably,
although a rapid kit exists for IL-6. The same is true of SNP
profiling. Our exploration suggests that we probably do not need
both a cytokine and SNP profile at this time, but the jury is
certainly not out. Yet, it cannot be anticipated that such detailed
physiotyping will be commonly performed at the bedside in the
foreseeable future. Therefore, it would seem appropriate to
expand data available to the DNF algorithms to include a larger
overlap with data used by currently available mortality prediction
tools. Indeed, one could conceive of DNF rules as representing
phenotypes, confined to data that is already available, and that
could be refined if more data were available to develop a more
complete set of rules. The level of sophistication with which these
phenotypes would be described would increase from purely
clinical, to phenotypes characterized by a combination of clinical,
laboratory, and genetic markers.
Our exploration was limited to 27 SNPs and 3 cytokines, and
several leukocytic surface markers in a subset of the population
therefore our representation of the cellular and genetic component
to physiotyping is very limited. Other analytes are now becoming
available in this database, including SNPs for coagulation genes,
which are definitely strong predictors of outcome. This can be
understood mechanistically when that considering excessive
activation of coagulation, with subsequent microthrombosis and
perfusion deficit, is a plausible cause of cellular energetic failure
with ensuing organ dysfunction [11].
It can be argued that 90-day mortality is an inappropriate
outcome and that one would expect early physiotyping to perform
better on predicting outcome on a shorter time scale. However, it is
apparent, especially in this dataset that our current concept of what
constitute acute illness extends well beyond the intensive care unit,
or a specific hospitalization episode [51,52]. It makes entire sense
that wider genetic screens might be more predictive than early
physiology in teasing late death. Different classes of predicative
models are required to tease out time-varying hazard ratios [53].
Such a study would be a natural extension of this work. It could also
be argued that predicting mortality does not mean the ability to
predict response to treatment, a holy grail of acute care medicine.
Any signal in the possible effectiveness of immunomodulatory
therapies has been observed in the sickest individuals. [54,55],
suggesting the relevance of more detailed physiotyping in the
prediction of the response to treatment. This is also suggested by in
silico studies [7]. The DNF formulation can generally applied to a
variety of outcomes of clinical interest. For example, enrollment and
decision points in clinical trials are often criteria-based. The
applications of data-driven rules computed from DNF learning to
the profiles of patients currently screened or enrolled in clinical trials
could be quite helpful to assist clinical trial design, enrich
enrollment, or eventually adapt design based on observed response.
Table 5. DNF of the patient mortality.
Hospmort mortality
(model 8)
(Ssday1w1) ((Ssday1w0)AND(Npctw1)AND(NIL6 2w1))~93:6=82:3
Hospmort mortality
(model 7)
((Ssday1w1) ((Ssday1w0)AND(IL1R901827 A15!~A=G)AND(Nagew1)AND(NIL10 1)w1))~ 91:0=89:3
90-day mortality
(model 8)
((Ssday1w0)AND(Npctw1)) ((IL1R895495 AG !~A=G)AND(Npctw1)AND(Nap3~4)AND(chronic tw0))~70:1=76:4
90-day mortality
(model 7)
((Ssday1w0)AND(Nap3w0)AND(Npctw0)) (IL1R901827 A15 !~A)AND(Nap3~4)AND(Npctw0)AND(Nfactor 0w0))~69:6=76:6
doi:10.1371/journal.pone.0089053.t005
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In conclusion, we presented DNF as a novel prediction tool
which perform comparably or better than currently available tools
to predict outcome in patients with hospitalized community
acquired pneumonia, and which presents the added advantage to
be criteria-based and easily implemented as a decision support
system at the bedside. We believe DNF are generally applicable to
a range of clinically relevant patient-centered outcomes. Despite its
apparent simplicity, DNF do require the input of expert
quantitative scientists to develop and implement.
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